Kiniksa Pharmaceuticals (KNSA)
(Delayed Data from NSDQ)
$19.22 USD
+0.16 (0.84%)
Updated Jun 10, 2024 04:00 PM ET
After-Market: $19.22 0.00 (0.00%) 4:36 PM ET
3-Hold of 5 3
D Value C Growth D Momentum D VGM
Brokerage Reports
Kiniksa Pharmaceuticals, Ltd. [KNSA]
Reports for Purchase
Showing records 21 - 40 ( 110 total )
Company: Kiniksa Pharmaceuticals, Ltd.
Industry: Medical - Biomedical and Genetics
ARCALYST Scores a Triple and Looks to Overseas Expansion
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Kiniksa Pharmaceuticals, Ltd.
Industry: Medical - Biomedical and Genetics
Highlights Pipeline Progress While We Await ARCALYST Updates
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Kiniksa Pharmaceuticals, Ltd.
Industry: Medical - Biomedical and Genetics
KNSA Drops ARDS but ARCALYST Remains the Value Driver
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Kiniksa Pharmaceuticals, Ltd.
Industry: Medical - Biomedical and Genetics
ARCALYST Bats Two for Two; Pipeline Progress on Point
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Kiniksa Pharmaceuticals, Ltd.
Industry: Medical - Biomedical and Genetics
Company: Kiniksa Pharmaceuticals, Ltd.
Industry: Medical - Biomedical and Genetics
Company: Kiniksa Pharmaceuticals, Ltd.
Industry: Medical - Biomedical and Genetics
Company: Kiniksa Pharmaceuticals, Ltd.
Industry: Medical - Biomedical and Genetics
ARCALYST Beats in Q2, Looking for Gold in Q3
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D